Procept BioRobotics Corporation Secures New CPT Code for Aquablation Treatment

Summary

Procept BioRobotics Corporation announced that its Aquablation therapy for benign prostatic hyperplasia has been granted a Class I CPT code effective January 1, 2026. This new classification replaces the previous Class III code, which is expected to facilitate surgical adoption and patient access. The proposed Medicare national average payment for physician fees is approximately $540, with the final rule expected in November 2025.Reuters

Impact Analysis

The granting of the Class I CPT code represents a significant regulatory milestone for Procept BioRobotics. First-order effects include a likely increase in the adoption of Aquablation therapy by surgeons and enhanced accessibility for patients, potentially leading to higher revenue streams for the company. The Medicare national average payment proposal further supports financial incentives for healthcare providers, thereby bolstering the therapy’s market position. Second-order effects could involve a ripple effect in the medical device industry, as other companies may seek similar advancements or face competitive pressure to innovate. Investment opportunities could arise from stock appreciation due to expected increased sales and market penetration. However, investors should be aware of potential risks such as changes in regulatory landscapes or healthcare reimbursement policies that could affect future earnings.Reuters